Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

VRTX

Vertex Pharmaceuticals, Inc.

May 09 • 04:00PM ET

418.99

Dollar change +0.17
Percentage change 0.04	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ IVV VUG IBB JEPI VHT IWF QUAL

Index	NDX, S&P 500	P/E	27.18	EPS (ttm)	15.41	Insider Own	0.24%	Shs Outstand	257.70M	Perf Week	4.71%
Market Cap	108.23B	Forward P/E	22.93	EPS next Y	18.28	Insider Trans	-17.94%	Shs Float	257.69M	Perf Month	5.39%
Income	4.02B	PEG	2.12	EPS next Q	4.16	Inst Own	94.16%	Short Float	1.56%	Perf Quarter	-0.96%
Sales	10.17B	P/S	10.64	EPS this Y	11.28%	Inst Trans	1.21%	Short Ratio	3.84	Perf Half Y	10.77%
Book/sh	71.80	P/B	5.84	EPS next Y	7.83%	ROA	18.74%	Short Interest	4.03M	Perf Year	21.51%
Cash/sh	39.38	P/C	10.64	EPS next 5Y	12.80%	ROE	24.38%	52W Range	320.01 - 448.40	Perf YTD	2.97%
Dividend Est.	-	P/FCF	29.12	EPS past 5Y	11.42%	ROI	20.86%	52W High	-6.56%	Beta	0.39
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	27.16%	Gross Margin	86.85%	52W Low	30.93%	ATR (14)	8.73
Dividend Ex-Date	-	Current Ratio	3.50	EPS Y/Y TTM	22.70%	Oper. Margin	40.81%	RSI (14)	65.89	Volatility	2.74% 1.97%
Employees	5400	Debt/Eq	0.04	Sales Y/Y TTM	12.74%	Profit Margin	39.51%	Recom	1.94	Target Price	464.29
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	56.65%	Payout	0.00%	Rel Volume	0.64	Prev Close	418.82
Sales Surprise	4.24%	EPS Surprise	16.87%	Sales Q/Q	14.21%	Earnings	May 06 AMC	Avg Volume	1.05M	Price	418.99
SMA20	4.83%	SMA50	2.68%	SMA200	8.73%	Trades		Volume	676,005	Change	0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold
Jan-24-24	Downgrade	Canaccord Genuity	Hold → Sell	$332 → $379
Dec-14-23	Reiterated	RBC Capital Mkts	Sector Perform	$347 → $379
May-30-23	Initiated	William Blair	Outperform	$382
May-04-23	Resumed	Piper Sandler	Overweight	$385
Mar-21-23	Initiated	Bernstein	Outperform	$344
Jan-18-23	Initiated	Canaccord Genuity	Hold	$311
Jan-17-23	Upgrade	SVB Leerink	Mkt Perform → Outperform	$374
Dec-19-22	Downgrade	Jefferies	Buy → Hold	$340
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$365
Jun-01-22	Upgrade	Maxim Group	Hold → Buy	$325
May-23-22	Initiated	SVB Leerink	Mkt Perform	$265
May-06-22	Downgrade	Robert W. Baird	Outperform → Neutral	$250
May-03-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$250
Feb-03-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$269

Show Previous Ratings

May-09-24 04:00PM	Alpine Immune Sciences Reports First Quarter 2024 Financial Results (Business Wire)
01:04AM	Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight (GuruFocus.com)
May-08-24 12:36PM	Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets (Insider Monkey)
09:30AM	Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:43AM	5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip (Motley Fool)
04:06PM	Loading…
May-07-24 04:06PM	Vertex's Pain Drug Could Be Worth Up To $11.4 Billion Ongoing Debate Sparks Shares (Investor's Business Daily)
02:21PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
11:24AM	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:50AM	Q1 2024 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:44AM	Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales (Zacks)
06:30AM	Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 (MT Newswires)
06:29AM	Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 (MT Newswires)
05:45AM	Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating (MT Newswires)
05:45AM	Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating (MT Newswires)
05:41AM	RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating (MT Newswires)
05:41AM	Loading…
05:41AM	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating (MT Newswires)
05:41AM	Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating (MT Newswires)
03:08AM	Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)
May-06-24 08:45PM	Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript (Motley Fool)
06:33PM	UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments (Reuters)
05:42PM	Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions (GuruFocus.com)
05:10PM	Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
04:59PM	Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key (Investor's Business Daily)
04:38PM	Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase (MT Newswires)
04:17PM	Vertex: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook (Investor's Business Daily)
04:11PM	Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments (Reuters)
04:01PM	Vertex Reports First Quarter 2024 Financial Results (Business Wire)
02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
May-05-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
06:55AM	Loading…
06:55AM	3 No-Brainer Stocks to Buy in May (Motley Fool)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-03-24 07:01PM	Insider Sale at Vertex Pharmaceuticals Inc (VRTX): Director Sangeeta Bhatia Sells Shares (GuruFocus.com)
02:18PM	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar (InvestorPlace)
08:45AM	3 Growth Stocks You'll Kick Yourself for Not Buying Today (InvestorPlace)
06:15AM	Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar (InvestorPlace)
May-02-24 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
07:15AM	3 Biotech Stocks to Buy and Hold Through 2030 and Beyond (Motley Fool)
May-01-24 09:15AM	Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-30-24 05:36AM	Vertex (VRTX) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-29-24 10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-28-24 08:45AM	2 Top Growth Stocks to Buy Right Now and Hold Forever (Motley Fool)
Apr-27-24 05:50AM	Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades. (Motley Fool)
Apr-26-24 12:22PM	Pioneer Institute study finds IRA discourages non-opioid drug innovation (Pharmaceutical Technology)
12:11PM	Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants (MT Newswires)
11:43AM	Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older (Business Wire)
Apr-25-24 05:50PM	Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
09:45AM	2 Fantastic Growth Stocks to Buy Right Now (Motley Fool)
07:00AM	Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth (Reuters)
Apr-24-24 05:50AM	Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
08:09AM	Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies (Zacks)
06:05AM	Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? (Motley Fool)
12:45AM	VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES (PR Newswire)
Apr-22-24 11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
09:03AM	Making Sense of Amazon CEO Andy Jassy's Latest Letter (Motley Fool)
07:16AM	If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
05:52AM	Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now (Motley Fool)
Apr-20-24 09:45AM	2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever (Motley Fool)
06:48AM	3 Relatively Safe Growth Stocks You Can Buy and Hold (Motley Fool)
Apr-19-24 05:50PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know (Zacks)
11:57AM	Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug (Zacks)
04:30AM	Is Vertex Pharmaceuticals Stock a Millionaire Maker? (Motley Fool)
Apr-18-24 08:30AM	Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? (Motley Fool)
08:00AM	Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain (Business Wire)
07:00AM	Vertex begins bid for US approval of non-opioid painkiller (BioPharma Dive)
Apr-16-24 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
09:30AM	Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Apr-15-24 12:00PM	Vertex Pharma scientist talks about the long road to developing non-addictive painkillers (Associated Press Finance)
09:15AM	Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock (Motley Fool)
09:04AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
Apr-13-24 08:47AM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 10:55AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video)
04:18PM	Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It (Investor's Business Daily)
01:59PM	Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands (The Wall Street Journal)
11:58AM	Top Stock Movers Now: Nike, Constellation Brands, Fastenal, and More (Investopedia)
11:03AM	Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says. (Barrons.com)
09:47AM	These Stocks Are Moving the Most Today (Barrons.com)
09:39AM	Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer (Bloomberg)
09:15AM	Vertex Pharmaceuticals: Buy, Sell, or Hold? (Motley Fool)
07:34AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:17AM	US STOCKS-Futures slip as rate-cut hopes ebb (Reuters)
02:00AM	PRESS DIGEST- Wall Street Journal - April 11 (Reuters)
Apr-10-24 10:34PM	Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B Key Level to Watch (Investopedia)
07:05PM	Biotech giant Vertex bought Alpine in a cash deal of $4.9 billion (Quartz)
06:00PM	Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
05:47PM	Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion (The Wall Street Journal)
05:14PM	Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal (Investor's Business Daily)
04:19PM	Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal (Reuters)
04:16PM	UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal (Reuters)
04:06PM	Vertex to acquire Alpine Immune Sciences for $4.9 bln (Reuters)
04:01PM	Vertex Enters Into Agreement to Acquire Alpine Immune Sciences (Business Wire)
01:34PM	Vertex to buy kidney disease drugmaker Alpine for $4.9B (BioPharma Dive)
Apr-09-24 04:05PM	Vertex to Announce First Quarter 2024 Financial Results on May 6 (Business Wire)
10:07AM	This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy? (Motley Fool)
10:00AM	Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics (Motley Fool)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bhatia Sangeeta N.	Director	May 02 '24	Sale	402.95	467	188,178	4,435	May 03 04:05 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Apr 02 '24	Sale	419.00	240	100,560	7,500	Apr 03 04:02 PM
Arbuckle Stuart A	EVP, COO	Feb 26 '24	Sale	425.70	5,034	2,142,974	49,691	Feb 27 04:37 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 26 '24	Sale	425.70	4,239	1,804,542	25,813	Feb 27 04:24 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 26 '24	Sale	425.70	3,004	1,278,803	55,325	Feb 27 04:59 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 26 '24	Sale	425.70	883	375,893	7,965	Feb 27 04:29 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 26 '24	Sale	425.70	883	375,893	15,972	Feb 27 04:44 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 26 '24	Sale	425.70	354	150,698	55,804	Feb 27 05:02 PM
Arbuckle Stuart A	EVP, COO	Feb 21 '24	Sale	421.77	3,603	1,519,637	59,439	Feb 23 04:12 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 21 '24	Sale	421.77	3,191	1,345,868	60,798	Feb 23 04:20 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 21 '24	Sale	421.77	3,002	1,266,154	34,022	Feb 23 04:10 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 21 '24	Sale	421.77	1,201	506,546	18,509	Feb 23 04:16 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 21 '24	Sale	421.77	360	151,837	59,467	Feb 23 04:28 PM
Arbuckle Stuart A	EVP, COO	Feb 20 '24	Sale	420.79	4,804	2,021,475	63,042	Feb 21 04:19 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 20 '24	Sale	420.79	4,254	1,790,041	63,989	Feb 21 04:38 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 20 '24	Sale	420.79	4,002	1,684,002	37,024	Feb 21 04:13 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 20 '24	Sale	420.79	801	337,053	19,710	Feb 21 04:23 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 20 '24	Sale	420.79	480	201,979	59,827	Feb 21 04:43 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 15 '24	Sale	419.16	4,655	1,951,190	17,896	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 14 '24	Sale	419.04	4,356	1,825,338	22,551	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 13 '24	Sale	419.13	737	308,899	26,907	Feb 14 04:04 PM
Arbuckle Stuart A	EVP, COO	Feb 12 '24	Sale	420.24	4,295	1,804,931	75,718	Feb 13 04:51 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 12 '24	Sale	420.24	3,222	1,354,013	74,364	Feb 13 05:15 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 12 '24	Sale	420.24	3,145	1,321,655	47,588	Feb 13 04:46 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 12 '24	Sale	419.51	2,656	1,114,205	27,644	Feb 14 04:04 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 12 '24	Sale	418.77	1,738	727,822	18,280	Feb 13 04:56 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 12 '24	Sale	420.24	1,374	577,410	9,676	Feb 13 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 12 '24	Sale	420.24	913	383,679	23,137	Feb 13 04:54 PM
LEIDEN JEFFREY M	Executive Chairman	Jan 08 '24	Sale	419.07	6,648	2,785,977	2,423	Jan 10 04:06 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jan 02 '24	Sale	405.00	3,000	1,215,000	43,693	Jan 04 04:17 PM
Kewalramani Reshma	CEO & President	Dec 15 '23	Option Exercise	181.83	17,135	3,115,593	125,846	Dec 19 04:15 PM
Kewalramani Reshma	CEO & President	Dec 15 '23	Sale	407.00	17,135	6,973,945	108,711	Dec 19 04:15 PM
Arbuckle Stuart A	EVP, COO	Dec 13 '23	Option Exercise	187.53	8,603	1,613,321	65,159	Dec 15 04:20 PM
LEIDEN JEFFREY M	Executive Chairman	Dec 13 '23	Sale	399.42	13,354	5,333,799	9,071	Dec 15 04:33 PM
Arbuckle Stuart A	EVP, COO	Dec 13 '23	Sale	399.00	8,603	3,432,597	56,556	Dec 15 04:20 PM
Kewalramani Reshma	CEO & President	Dec 13 '23	Sale	397.00	5,098	2,023,906	108,711	Dec 15 04:23 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 20 '23	Sale	349.88	3,000	1,049,640	46,693	Nov 21 04:07 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Nov 15 '23	Sale	369.92	35	12,947	58,814	Nov 17 04:16 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 15 '23	Sale	369.92	19	7,028	32,038	Nov 17 04:11 PM
Bozic Carmen	EVP and CMO	Nov 14 '23	Sale	380.82	5,650	2,151,633	29,302	Nov 16 04:15 PM
Kewalramani Reshma	CEO & President	Nov 13 '23	Sale	377.00	5,097	1,921,569	113,809	Nov 15 04:16 PM
SACHS BRUCE I	Director	Nov 06 '23	Option Exercise	127.54	11,250	1,434,825	51,250	Nov 08 04:11 PM
SACHS BRUCE I	Director	Nov 06 '23	Sale	385.00	11,250	4,331,250	40,000	Nov 08 04:11 PM
Bozic Carmen	EVP and CMO	Oct 31 '23	Sale	355.92	5,651	2,011,304	34,952	Nov 02 04:07 PM
Bozic Carmen	EVP and CMO	Oct 17 '23	Sale	373.25	5,651	2,109,236	40,603	Oct 19 04:18 PM
Bhatia Sangeeta N.	Director	Oct 17 '23	Sale	375.00	243	91,125	3,901	Oct 19 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Oct 16 '23	Sale	374.00	12,962	4,847,788	22,425	Oct 18 04:17 PM
Bhatia Sangeeta N.	Director	Oct 06 '23	Sale	360.00	242	87,120	4,144	Oct 11 04:14 PM
Bozic Carmen	EVP and CMO	Oct 03 '23	Sale	345.28	5,651	1,951,177	46,254	Oct 05 04:30 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '23	Sale	346.76	610	211,524	10,569	Oct 03 04:07 PM
Bozic Carmen	EVP and CMO	Sep 19 '23	Sale	351.00	5,651	1,983,501	51,905	Sep 21 04:15 PM
Bozic Carmen	EVP and CMO	Sep 05 '23	Sale	352.66	5,651	1,992,882	57,556	Sep 07 04:29 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Aug 23 '23	Sale	355.00	2,500	887,500	48,637	Aug 25 04:14 PM
Kearney Terrence C	Director	Aug 10 '23	Option Exercise	127.54	10,000	1,275,400	16,536	Aug 14 04:09 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 10 '23	Sale	350.00	10,031	3,510,850	58,814	Aug 14 04:05 PM
Kearney Terrence C	Director	Aug 10 '23	Sale	350.00	10,000	3,500,000	6,536	Aug 14 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Aug 10 '23	Sale	345.79	5,750	1,988,293	51,137	Aug 14 04:08 PM
Bhatia Sangeeta N.	Director	Aug 09 '23	Sale	345.51	242	83,613	4,386	Aug 11 04:05 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 09 '23	Sale	345.51	63	21,767	32,038	Aug 11 04:05 PM
SACHS BRUCE I	Director	Jul 17 '23	Option Exercise	127.54	11,250	1,434,825	51,250	Jul 18 04:17 PM
SACHS BRUCE I	Director	Jul 17 '23	Sale	356.75	11,250	4,013,459	40,000	Jul 18 04:17 PM
Kewalramani Reshma	CEO & President	Jul 17 '23	Sale	355.00	7,828	2,778,940	118,906	Jul 18 04:13 PM
Arbuckle Stuart A	EVP, COO	Jun 15 '23	Option Exercise	187.53	8,603	1,613,321	65,159	Jun 20 04:07 PM
Arbuckle Stuart A	EVP, COO	Jun 15 '23	Sale	349.00	8,603	3,002,447	56,556	Jun 20 04:07 PM
Ambrose Kristen	SVP & Chief Accounting Officer	May 30 '23	Sale	329.82	289	95,318	6,838	Jun 01 04:12 PM
Arbuckle Stuart A	EVP, COO	May 30 '23	Sale	329.82	82	27,045	56,556	Jun 01 04:16 PM

Open in Screener

ETNB

89bio Inc

May 09 • 04:00PM ET

9.11

Dollar change +0.08
Percentage change 0.89	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO IBB VTWO LABU SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	7.00%	Shs Outstand	93.27M	Perf Week	2.82%
Market Cap	867.45M	Forward P/E	-	EPS next Y	-2.58	Insider Trans	22.92%	Shs Float	88.56M	Perf Month	-13.57%
Income	-142.19M	PEG	-	EPS next Q	-0.50	Inst Own	102.09%	Short Float	12.66%	Perf Quarter	7.81%
Sales	0.00M	P/S	-	EPS this Y	-2.97%	Inst Trans	8.69%	Short Ratio	9.84	Perf Half Y	5.20%
Book/sh	5.75	P/B	1.58	EPS next Y	-25.16%	ROA	-35.86%	Short Interest	11.21M	Perf Year	-49.58%
Cash/sh	6.08	P/C	1.50	EPS next 5Y	11.00%	ROE	-41.33%	52W Range	6.57 - 22.93	Perf YTD	-18.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.24%	ROI	-25.26%	52W High	-60.27%	Beta	1.03
Dividend TTM	-	Quick Ratio	20.04	Sales past 5Y	0.00%	Gross Margin	-	52W Low	38.56%	ATR (14)	0.53
Dividend Ex-Date	-	Current Ratio	20.04	EPS Y/Y TTM	43.10%	Oper. Margin	0.00%	RSI (14)	44.41	Volatility	4.95% 5.31%
Employees	70	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	31.78
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-2.97%	Payout	-	Rel Volume	0.52	Prev Close	9.03
Sales Surprise	-	EPS Surprise	-18.63%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	1.14M	Price	9.11
SMA20	0.60%	SMA50	-14.99%	SMA200	-20.97%	Trades		Volume	590,347	Change	0.89%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Buy	$30
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $15
Oct-10-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-28-23	Initiated	UBS	Buy	$36
Jun-13-23	Initiated	Evercore ISI	Outperform	$49
May-12-22	Upgrade	Raymond James	Outperform → Strong Buy	$33 → $12
Dec-20-21	Initiated	H.C. Wainwright	Buy	$46
Oct-26-21	Resumed	Cantor Fitzgerald	Overweight	$49
Jul-29-21	Resumed	BTIG Research	Buy	$60
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$65 → $35
Apr-21-21	Initiated	Cantor Fitzgerald	Overweight	$58
Oct-19-20	Initiated	Raymond James	Strong Buy	$65
Sep-25-20	Upgrade	BofA Securities	Neutral → Buy	$37 → $43
Jul-31-20	Initiated	Piper Sandler	Overweight	$54
Jul-23-20	Initiated	BTIG Research	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$58
Dec-09-19	Initiated	SVB Leerink	Outperform
Dec-09-19	Initiated	RBC Capital Mkts	Outperform
Dec-09-19	Initiated	Oppenheimer	Outperform
Dec-09-19	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

May-09-24 10:54PM	ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 11:56PM	Jump on the Bandwagon, Says Bank of America About These 2 Stock Picks (TipRanks)
04:05PM	89bio to Participate in the BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-06-24 12:00PM	All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy (Zacks)
04:05PM	Loading…
May-02-24 04:05PM	89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH (GlobeNewswire)
Apr-17-24 04:05PM	89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors (GlobeNewswire)
Apr-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-24 07:01PM	89bio Inc CEO Rohan Palekar Sells 52,718 Shares (GuruFocus.com)
Mar-27-24 08:00AM	89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal) -6.80%
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis (GlobeNewswire)
Mar-08-24 04:05PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-24 01:34PM	Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Crispin Odey, Glen Kacher, Julian Robertson, Nelson Peltz, Brevan Howard Asset Management, SLR Investment Corp. (SLRC), 89bio, Inc. (ETNB), and More (Insider Monkey) +7.34%
04:05PM	Loading…
Mar-05-24 04:05PM	89bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -14.81%
09:55AM	Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade (Zacks)
09:30AM	89BIO (ETNB) Just Overtook the 200-Day Moving Average (Zacks)
Mar-04-24 04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily) +9.11%
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
Mar-02-24 04:31AM	89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... (GuruFocus.com)
Feb-29-24 04:05PM	89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-06-24 04:05PM	89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -17.04%
Feb-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 09:35AM	89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-10-24 09:55AM	Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect? (Zacks)
Dec-19-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-23 07:30AM	89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Loading…
Dec-07-23 07:00AM	89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-06-23 04:36PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-04-23 07:00AM	89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 (GlobeNewswire) +7.74%
Nov-27-23 08:00AM	89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Nov-21-23 04:01PM	89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference (GlobeNewswire)
Nov-12-23 12:15PM	89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 07:28AM	89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023 (GuruFocus.com)
Nov-08-23 04:01PM	89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.27%
Oct-17-23 08:00AM	89bio to Participate in the H.C. Wainwright 7 Annual NASH Investor Conference (GlobeNewswire)
Oct-11-23 03:49AM	Texas Instruments margins in for a squeeze; Silk Road walloped: 5 big analyst cuts (Investing.com) -13.04%
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -37.06%
Oct-03-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-23 08:00AM	89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Sep-20-23 08:00AM	89bio to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -9.84%
Sep-05-23 08:00AM	89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 04:01PM	89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-23 04:30PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
Jun-24-23 05:05AM	89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine (GlobeNewswire)
05:01AM	Data from 89bios ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress (GlobeNewswire)
Jun-07-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023 (GlobeNewswire)
May-29-23 09:35AM	89BIO (ETNB) Just Overtook the 20-Day Moving Average (Zacks)
May-23-23 08:00AM	89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
May-13-23 08:53AM	Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain (Simply Wall St.)
May-05-23 09:55AM	Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know (Zacks)
May-04-23 04:05PM	89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-29-23 08:25AM	3 Biotech Buyout Targets to Watch (Motley Fool)
Apr-13-23 09:55AM	Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks) +6.78%
09:40AM	Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-02-23 08:27AM	Independent Director Michael Hayden Just Bought 41% More Shares In 89bio, Inc. (NASDAQ:ETNB) (Simply Wall St.)
Mar-24-23 10:57AM	Why Shares of 89bio Soared This Week (Motley Fool)
07:00AM	89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock (GlobeNewswire)
Mar-22-23 04:16PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +25.16%
04:09PM	Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up (Investor's Business Daily)
09:14AM	89bio Rockets 30% And Akero Dives On A Scorching Battle In Liver Disease (Investor's Business Daily)
07:00AM	89bios Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks (GlobeNewswire)
Mar-21-23 05:10PM	12 Best Biotech Stocks To Buy Under $20 (Insider Monkey) -7.06%
Mar-15-23 09:55AM	Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks) -9.29%
Mar-10-23 08:00AM	89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.96%
Mar-04-23 01:30PM	89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (GlobeNewswire)
Feb-21-23 08:00AM	89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (GlobeNewswire)
Feb-08-23 08:00AM	89bio to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-24-23 09:28AM	Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag (Zacks)
Jan-22-23 09:21AM	With stock up 19%, Insiders of 89bio, Inc. (NASDAQ:ETNB) must be wishing they had bought more last year (Simply Wall St.)
Jan-04-23 04:01PM	89bio Provides Business Update and Outlook for 2023 (GlobeNewswire)
Dec-12-22 06:30PM	89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Nov-25-22 04:04AM	Analysts Say These 2 Strong Buy Stocks Are Their Top Picks for 2023 (TipRanks)
Nov-10-22 04:05PM	89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-22 01:00PM	89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-13-22 08:00AM	89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference (GlobeNewswire)
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 (Insider Monkey) +5.66%
Sep-07-22 08:00AM	89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +5.79%
Sep-01-22 10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-26-22 08:05AM	89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control (Benzinga)
06:00AM	89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022 (GlobeNewswire)
Aug-18-22 08:00AM	89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH (GlobeNewswire) +9.49%
Aug-15-22 08:23AM	Insiders at 89bio, Inc. (NASDAQ:ETNB) recouped some losses this week after buying this year, still down US$20k (Simply Wall St.) +8.97%
Aug-11-22 08:00AM	89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-11-22 02:15PM	This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations (Benzinga) -7.56%
Jul-05-22 08:05AM	What Kind Of Shareholders Hold The Majority In 89bio, Inc.'s (NASDAQ:ETNB) Shares? (Simply Wall St.) -6.79%
08:00AM	89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
Jun-29-22 01:47AM	89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
Jun-28-22 04:02PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
04:01PM	89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
Jun-21-22 08:00AM	89bio to Present Additional Pegozafermin Data at EASL International Liver Congress 2022 (GlobeNewswire)
Jun-02-22 10:57AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $30 (Or More) (TipRanks) +15.17%
May-11-22 04:05PM	89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.73%

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Option Exercise	1.93	25,000	48,250	511,889	Apr 03 04:01 PM
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Sale	10.91	52,718	575,153	459,171	Apr 03 04:01 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 04 '24	Buy	15.35	1,350,000	20,722,500	12,431,584	Mar 06 05:40 PM
PALEKAR ROHAN	Chief Executive Officer	Feb 26 '24	Sale	10.76	4,477	48,173	486,889	Feb 28 06:43 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 29 '23	Option Exercise	1.93	50,000	96,500	351,225	Jan 03 04:54 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 29 '23	Sale	11.20	50,000	560,000	301,225	Jan 03 04:54 PM
LAPORTE KATHLEEN	Director	Jul 17 '23	Option Exercise	2.64	12,500	33,000	12,500	Jul 18 06:04 PM
LAPORTE KATHLEEN	Director	Jul 17 '23	Sale	18.80	12,500	235,000	0	Jul 18 06:04 PM
PALEKAR ROHAN	Chief Executive Officer	Jun 05 '23	Option Exercise	1.93	15,000	28,950	301,978	Jun 07 05:04 PM
PALEKAR ROHAN	Chief Executive Officer	Jun 05 '23	Sale	20.00	15,000	300,000	286,978	Jun 07 05:04 PM
Atkinson Edward Morrow III	Director	Jun 01 '23	Option Exercise	2.61	6,250	16,312	6,250	Jun 05 05:03 PM
Atkinson Edward Morrow III	Director	Jun 01 '23	Sale	17.91	6,250	111,938	0	Jun 05 05:03 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

VRTX

Vertex Pharmaceuticals, Inc.

ETNB

89bio Inc

Upgrade your FINVIZ experience